{
    "2020-11-24": [
        [
            {
                "time": "",
                "orginal_text": "医药生物行业周报：板块持续回调 逢低布局景气度高的细分赛道",
                "features": {
                    "keywords": [
                        "医药生物",
                        "板块回调",
                        "逢低布局",
                        "景气度高",
                        "细分赛道"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "【异动股】药明康德(02359-HK)跌3.09%",
                "features": {
                    "keywords": [
                        "药明康德",
                        "股价下跌",
                        "异动股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "创新药行业周报：贝达药业ALK抑制剂恩沙替尼获批",
                "features": {
                    "keywords": [
                        "创新药",
                        "贝达药业",
                        "恩沙替尼",
                        "获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "医药生物行业周报：医保谈判进入关键阶段 创新药可及性进一步提升",
                "features": {
                    "keywords": [
                        "医药生物",
                        "医保谈判",
                        "创新药",
                        "可及性提升"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "医药股再度走弱，石药集团跌超5%",
                "features": {
                    "keywords": [
                        "医药股",
                        "走弱",
                        "石药集团",
                        "股价下跌"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "新兴品牌突围战：知识产权才是最后的“生死线”",
                "features": {
                    "keywords": [
                        "新兴品牌",
                        "知识产权",
                        "生死线"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}